trial · primary record
Golidocitinib
Peripheral T Cell Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2029-07-05 |
| Primary endpoint | Safety and Adverse Events |
| Registry ID | NCT06630091 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:50.867Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06630091
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.